Comparison 2. RISPERIDONE versus ARIPIPRAZOLE - all data short term.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state: 1a. No clinically significant response (as defined by the original studies)	2	384	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.62, 1.24]
2 Global state: 1b. No clinically important change (as defined by the original studies)	2	384	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.62, 1.24]
3 Leaving the study early	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 due to any reason	2	384	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.79, 1.41]
3.2 due to adverse events	2	384	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.39, 1.61]
3.3 due to inefficacy	2	384	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.41, 1.93]
4 Mental state: 1a. General - average endpoint score (PANSS total, high = poor)	2	372	Mean Difference (IV, Random, 95% CI)	−1.5 [−5.96, 2.96]
5 Mental state: 2. Positive symptoms average endpoint score (PANSS positive, high = poor)	2	372	Mean Difference (IV, Random, 95% CI)	−1.24 [−2.74, 0.26]
6 Mental state: 3. Negative symptoms - average endpoint score - (PANSS negative, high = poor)	2	372	Mean Difference (IV, Random, 95% CI)	0.45 [−0.87, 1.78]
7 Adverse effects: 1. General - at least one adverse effect	2	384	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.95, 1.09]
8 Adverse effects: 2a. Cardiac effects - QTc prolongation	1	301	Risk Ratio (M-H, Random, 95% CI)	14.21 [0.74, 272.45]
9 Adverse effects: 2b. Cardiac effects - QTc abnormalities - change from baseline in ms	2	383	Mean Difference (IV, Random, 95% CI)	7.19 [2.19, 12.19]
10 Adverse effects: 3a. Extrapyramidal effects	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
10.1 akathisia	2	384	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.21, 11.45]
10.2 dystonia	1	301	Risk Ratio (M-H, Random, 95% CI)	7.14 [2.41, 21.13]
10.3 extrapyramidal symptoms	2	384	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.68, 2.06]
10.4 parkinsonism	1	301	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.35]
10.5 tremor	1	301	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.05, 0.90]
10.6 use of antiparkinson medication	1	83	Risk Ratio (M-H, Random, 95% CI)	1.68 [0.89, 3.17]
11 Adverse effects: 3b. Extrapyramidal effects - scale measured	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
11.1 abnormal involuntary movement: AIMS (high = poor)	2	383	Mean Difference (IV, Random, 95% CI)	0.25 [−0.75, 1.24]
11.2 akathisia: Barnes Akathisia Scale (high = poor)	2	383	Mean Difference (IV, Random, 95% CI)	0.11 [−0.27, 0.49]
11.3 extrapyramidal symptoms: Simpson-Angus Scale (high = poor)	2	383	Mean Difference (IV, Random, 95% CI)	0.70 [−0.82, 2.22]
12 Adverse effects: 4a. Prolactin associated side effects	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
12.1 abnormally high prolactin value	1	301	Risk Ratio (M-H, Random, 95% CI)	26.23 [12.64, 54.46]
12.2 dysmenorrhea	1	91	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.02, 5.91]
13 Adverse effects: 4b. Prolactin - change from baseline in ng/ml	2	383	Mean Difference (IV, Random, 95% CI)	54.71 [49.36, 60.06]
14 Adverse effects: 5a. Metabolic effects - cholesterol - change from baseline in mg/dl	1	83	Mean Difference (IV, Random, 95% CI)	22.3 [4.91, 39.69]
15 Adverse effects: 5b. Metabolic effects - glucose - change from baseline in mg/dl	1	83	Mean Difference (IV, Random, 95% CI)	−6.8 [−19.70, 6.10]
16 Adverse effects: 5c. Metabolic effects - weight gain of 7% or more of total body weight	2	384	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.55, 3.07]
17 Adverse effects: 5d. Metabolic effects - weight gain - change from baseline in kg	2	383	Mean Difference (IV, Random, 95% CI)	0.54 [−0.15, 1.24]